If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Biomarker Enzyme Predicts Reduced Bone Formation in Patients With IBD: Presented at ASBMR By John Otrompke DENVER -- September 22, 2009 -- An enzyme, 11beta-hydroxysteroid dehydrogenase (type 1 [11beta-HSD1]), predicts bone loss in the lumbar spine of patients with inflammatory bowel disease (IBD) treated with prednisolone, according to a study presented here at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR). Glucocorticoids cause a detrimental effect on bone, including glucose-induced osteoporosis, according to a presentation by Mark Cooper, MD, University of Birmingham, Birmingham, United Kingdom, on September 14. Dr. Cooper and colleagues measured urinary 11beta-HSD activity in 89 adult patients. Of the patients, 34 had acute IBD and required oral prednisolone 10 mg/day for 1 week, 14 had stable IBD, and 41 were healthy. Patients who received prednisolone were randomised to receive either risedronate or placebo (20 patients in the prednisolone group received the placebo). Patients were then analysed for the ability of the enzyme to predict bone loss at 3 months. In the group receiving prednisolone, high activity levels in the 11beta-HSD1 biomarker corresponded with reduced bone loss at the lumbar spine; however, there was no such correlation at the total hip. In addition, the enzyme was associated with lower bone resorption at 8 weeks, but not with bone formation. Most likely, high levels of the enzyme in the colon enhanced the therapeutic effects of prednisolone on the underlying disease, the slides said. Funding for this study was provided by Procter and Gamble. [Presentation title: 11beta-Hydroxysteroid Dehydrogenase Activity Predicts Change in Spinal Bone Mineral Density in Patients With Inflammatory Bowel Disease Treated With Glucocorticoids. Abstract 1211]
|
